EC APPROVES TAKEDA'S COMPETACT FOR TYPE 2 DIABETES

The European Commission (EC) has granted Takeda Pharmaceutical marketing authorization for Competact, a fixed combination tablet of Actos (pioglitazone HCl) 15 mg and metformin HCl 850 mg, for Type 2 diabetes. Takeda submitted that application on Feb. 28 and received a positive opinion on June 2 from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Actos directly targets insulin resistance, a condition where the body does not efficiently use the insulin it produces, and metformin HCl acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with Type 2 diabetes manage their blood glucose levels.